Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Date:11/2/2011

of the Company's nucleotide prodrugs, the Company is reallocating discovery and development resources from its protease inhibitor program to the nucleotide program. The Company will continue to evaluate potential partnerships and licensing agreements for its protease inhibitor drug candidates and related intellectual property.

Upcoming Meetings/ConferencesAmerican Association for the Study of Liver Diseases Meeting (AASLD)
Idenix will present two posters at AASLD in San Francisco, California:

  • McCarville, et al, "Patterns of NS5B mutations in a 3-day clinical trial of HCV non-nucleoside polymerase inhibitor IDX375" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
  • McCarville, et al, "In vivo resistance profile of IDX320 after 3 days of dosing in genotype 1 HCV-infected patients" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT

  • HEP DART Meeting
    Idenix will have a presentation at HEP DART in Koloa, Hawaii:

  • Mayers, D. and Standring, D., "Combination DAA Strategies to Cure HCV" will be featured as an oral presentation on December 4, 2011

  • Credit Suisse 2011 Healthcare Conference
    Idenix management will present a corporate overview at the Credit Suisse 2011 Healthcare Conference on November 9, 2011 at 4:30 p.m. MST at the Arizona Biltmore Hotel, Phoenix.  

    The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

    ABOUT IDENIX
    Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and dev
    '/>"/>

    SOURCE Idenix Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
    2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
    3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
    4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
    5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
    6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
    8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
    10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... , Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present at ... Rodman & Renshaw 16 th ... ) Tuesday, September 9, 2014 at 9:10 a.m. ...
    (Date:9/2/2014)... Sept. 2, 2014  Amgen (NASDAQ: ... of a Marketing Authorization Application (MAA) to ... centralized procedure for talimogene laherparepvec seeking approval ... that is regionally or distantly metastatic. Talimogene laherparepvec ... an intralesional injection that is designed to ...
    (Date:9/2/2014)... SAN CARLOS, Calif. , Sept. 2, 2014 /PRNewswire/ ... a leader in synthetic biology, today announced that it ... Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: ... an enhanced production process for a specific family of ... manufacturing operations in France . This ...
    Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
    ... WaferGen Biosystems, Inc. (OTCBB:WGBSE), a leading developer of state-of-the-art ... second quarter ended June 30, 2011."During the second quarter, ... commercialize the SmartChip Real-Time PCR System.  We accomplished that ... placement financing of $30.6 million in equity and debt ...
    ... RANCHO CORDOVA, Calif., Sept. 12, 2011 ThermoGenesis Corp. (NASDAQ: ... and services that process and store adult stem cells in ... quarter and all of fiscal 2011. For the ... $5.4 million, compared to $7.2 million in the fourth quarter ...
    Cached Medicine Technology:WaferGen Reports Second Quarter 2011 Financial Results 2WaferGen Reports Second Quarter 2011 Financial Results 3WaferGen Reports Second Quarter 2011 Financial Results 4WaferGen Reports Second Quarter 2011 Financial Results 5WaferGen Reports Second Quarter 2011 Financial Results 6WaferGen Reports Second Quarter 2011 Financial Results 7WaferGen Reports Second Quarter 2011 Financial Results 8ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 2ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 3ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 4ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 5ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 6
    (Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
    (Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
    (Date:9/2/2014)... New York (PRWEB) September 02, 2014 With ... is making it easy to create a consistent look or ... physical structure, to the floor you walk on and the ... for all custom reclaimed wood designs. , “We’re excited ... to our product line. It saves time, adds consistency, and ...
    (Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
    (Date:9/2/2014)... AUGUSTA, Ga. A little white pill may help ... exercise capacity than their peers, even if their lungs ... drug sildenafil marketed as Revatio to treat pulmonary ... as a cocktail of over-the-counter antioxidants will help them ... makes exercise difficult for these patients. , "We ...
    Breaking Medicine News(10 mins):Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4
    ... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
    ... of,Hematology (ASH), the world,s largest professional society of ... notable,contributions to the genetic understanding of disease. Carlo ... intended to honor an individual,with a distinguished career ... receive the William Dameshek Prize, awarded to an ...
    ... HEI, Inc. (Nasdaq: HEII ),( http://www.heii.com ) ... with the,Securities and Exchange Commission to voluntarily deregister its ... expects that the,deregistration will be effective after 90 days, ... deregister. As a result of this filing, HEI,s,obligation to ...
    ... found in household fittings has been found to affect the ... will be required to determine if the presence of this ... the online open access journal BMC Genomics is the first ... profile. , Jose Russo and coworkers from the Fox Chase ...
    ... A new study in the Annals,of Emergency Medicine ("Increasing ... United States, 1993 to 2003") finds the rate of,elderly ... any,other group., Kenneth L. Noller, MD, President of ... statement about the,study on behalf of the Alliance of ...
    ... air pollution, especially diesel exhaust , , WEDNESDAY, Dec. 5 ... the health damage done by automotive air pollution, especially ... period of improving air quality in Switzerland, which started ... measurable benefits in lung function for adults as they ...
    Cached Medicine News:Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 3Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3
    Binocular indirect ophthalmic lenses. General diagnosis & treatment....
    ... Volk's super ... biomicroscopy lenses. Variable ... Provide unprecedented fundus ... addressing maximum potential ...
    Volk indirect lenses. Standard BIO examinations....
    ... Sanyo MLS-series top-loading autoclaves ... high pressure steam sterilizing ... unit that is particularly ... reliable, energy saving autoclaves ...
    Medicine Products: